After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Cramer is faithful to pet care drug maker Zoetis and he prefers Danaher over its split-off sibling Fortive.
Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.
BMO Capital Markets downgrades the pharmaceutical giant ahead of Q2 earnings as pricing pressure mounts and other potential headwinds begin to emerge.
Apoquel, the company's anti-itch drug, has been a very strong seller.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.